Physiologically Based Pharmacokinetic Modeling of Extracellular Vesicles
Biology, 2023 Extracellular vesicles (EVs) are lipid membrane bound-cell-derived structures that are a key player in intercellular communication and facilitate numerous cellular functions such as tumor growth, metastasis, immunosuppression, and angiogenesis.
Prashant Kumar +2 more
doaj +3 more sources
Pharmaceutics, 2021 Supinoxin is a novel anticancer drug candidate targeting the Y593 phospho-p68 RNA helicase, by exhibiting antiproliferative activity and/or suppression of tumor growth.
Yoo-Kyung Song +10 more
doaj +3 more sources
Unravelling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling [PDF]
Frontiers in Pharmacology, 2015 Physiologically based pharmacokinetic (PBPK) models integrate both chemical- and system-specific information into a mathematical framework, offering a mechanistic approach to predict the internal dose metrics of a chemical and an ability to perform ...
Xiaoxia eYang, Jeffrey W Fisher
doaj +3 more sources
Physiologically‐Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib [PDF]
CPT: Pharmacometrics & Systems PharmacologyA physiologically‐based pharmacokinetic (PBPK) model of niraparib and its primary metabolite using a relevant virtual cancer population is reported here. A series of in vitro experiments using liver S9, microsomes, and hepatocytes with various inhibitors
Gareth J. Lewis +3 more
doaj +2 more sources
Physiologically based pharmacokinetic modeling of POPs in Greenlanders
Environment International, 2014 Human exposure to persistent organic pollutants (POPs) and the potential health impact in the Arctic far from the emission sources have been highlighted in numerous studies.
Christian Sonne +5 more
doaj +3 more sources
Physiologically Based Pharmacokinetic Modeling and Therapeutic Drug Monitoring for Ertapenem Dose Optimization in Hypoalbuminemia Elderly Patients [PDF]
Drug Design, Development and TherapyXiaoyu Du,1 Zixuan Dong,1 Yumeng Li,1 Yin Wu,1,2 Huizhen Wu1,2 1School of Pharmacy, Graduate School of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China; 2Hebei Key Laboratory of Clinical Pharmacy, Department of Pharmacy, Hebei ...
Du X, Dong Z, Li Y, Wu Y, Wu H
doaj +2 more sources
Physiologically Based Pharmacokinetic Modeling in Patients With Hepatic Impairment: Are Changes in Bosutinib Exposure Profiles Driven by Altered Absorption or Distribution? [PDF]
CPT: Pharmacometrics & Systems PharmacologyBosutinib is an orally available Src/Abl tyrosine kinase inhibitor and has been approved for the treatment of patients with Ph + chronic myelogenous leukemia.
Chieko Muto +2 more
doaj +2 more sources
Physiologically Based Pharmacokinetic Modeling of Elexacaftor/Tezacaftor/Ivacaftor in Infants With Cystic Fibrosis [PDF]
CPT: Pharmacometrics & Systems PharmacologyIvacaftor is the only cystic fibrosis transmembrane conductance regulator modulator approved for infants ≥ 1 month. The elexacaftor/tezacaftor/ivacaftor combination, approved for children aged ≥ 2 years, has been shown to significantly slow CF ...
Ngoc Hoa Truong +16 more
doaj +2 more sources
Predicting Systemic and Liver Bosentan Exposure Using Physiologically‐Based Pharmacokinetic Modeling [PDF]
CPT: Pharmacometrics & Systems PharmacologyBosentan is the first approved oral medication for pulmonary arterial hypertension, yet the black‐box warning on its labeling implies a substantial risk of liver injury associated with bosentan exposure.
Miao‐Chan Huang +6 more
doaj +2 more sources
A Physiologically Based Pharmacokinetic Model for Capreomycin [PDF]
Antimicrobial Agents and Chemotherapy, 2012 ABSTRACTThe emergence of multidrug-resistant tuberculosis (MDR-TB) has led to a renewed interest in the use of second-line antibiotic agents. Unfortunately, there are currently dearths of information, data, and computational models that can be used to help design rational regimens for administration of these drugs.
B, Reisfeld +5 more
openaire +2 more sources